Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours [0.03%]
肾上腺恶性肿瘤中星鹤蛋白1高表达及其与生存预后的关联研究
Bárbara Dos Santos Passaia,Keli Lima,Jean Lucas Kremer et al.
Bárbara Dos Santos Passaia et al.
Adrenocortical carcinoma (ACC) is an aggressive endocrine cancer with few molecular predictors of malignancy and survival, especially in paediatric patients. Stathmin 1 (STMN1) regulates microtubule dynamics and has been involved in the mal...
Benzothiazole derivative bearing amide moiety induces p53-mediated apoptosis in HPV16 positive cervical cancer cells [0.03%]
苯并噻唑衍生物通过诱导HPV16阳性的宫颈癌细胞中p53介导的细胞凋亡发挥作用
Arusha Modi,Meenakshi Singh,Gopichand Gutti et al.
Arusha Modi et al.
In our previous study, we screened the anti-cancer properties of 10 benzothiazole derivatives in cervical cancer cell lines. In the present study, we aimed to delineate the mechanism of the apoptotic pathway (whether intrinsic or extrinsic)...
Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy [0.03%]
日本传统草药乐坤夏汤对接受以顺铂为基础的化学疗法的肺癌患者的厌食及血浆酰基化胃促生长素水平影响的前瞻性随机交叉试验研究
Tomoharu Yoshiya,Takahiro Mimae,Masaoki Ito et al.
Tomoharu Yoshiya et al.
Purpose Anorexia induced by cytotoxic chemotherapy on delayed phase is a highly frequent adverse event. We aimed to determine the effects of rikkunshito (RKT) on chemotherapy-induced anorexia (CIA) in patients with lung cancer. Methods This...
Randomized Controlled Trial
Investigational new drugs. 2020 Apr;38(2):485-492. DOI:10.1007/s10637-019-00836-x 2020
Identification of HGF as a novel target of miR-15a/16/195 in gastric cancer [0.03%]
微RNA-15a/16/195新的靶基因HGF的鉴定及其在胃癌中的作用研究
Dongying Liu,Haiyang Zhang,Shaohua Ge et al.
Dongying Liu et al.
Background Gastric malignancy is the third most frequently encountered cancer globally and have been documented to confer extremely poor prognosis, given their limited treatment options. The up-regulation of hepatocyte growth factor (HGF) h...
Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug [0.03%]
雷尼-SAHA杂合物作为多靶抗胶质母细胞瘤药物的研究发现
Jingkao Chen,Bingling Luo,Shijun Wen et al.
Jingkao Chen et al.
Glioblastoma multiforme (GBM) is the most common malignant tumor of the central nervous system (CNS). Effective treatments remain limited. Therefore, novel chemotherapy drugs with high efficiency and few adverse effects are urgently needed....
Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors [0.03%]
特异性免疫遗传学预测PD-1 / PD-L1检验点抑制剂的治疗结果
Sadal Refae,Jocelyn Gal,Nathalie Ebran et al.
Sadal Refae et al.
Background Checkpoint inhibitors bring marked benefits but only in a minority of patients and may also be associated with severe adverse events. Treatment outcome still cannot be faithfully predicted. The following study hypothesized that h...
A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer [0.03%]
广泛期小细胞肺癌一线诱导化疗后维持治疗对比监测的阿帕替尼随机II期临床试验
Hao Luo,Liang Zhang,Bo Yang et al.
Hao Luo et al.
Background The 5-year survival rate for extensive-disease small-cell lung carcinoma (ED-SCLC) is only 1%. Recently, apatinib exerted promising effects on cancer patients after failure of first-line chemotherapy. Methods This study enrolled ...
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001) [0.03%]
帕博利珠单抗治疗至少50%PD-L1阳性晚期非小细胞肺癌一线疗效和安全性回顾性队列研究(HOPE-001)
Motohiro Tamiya,Akihiro Tamiya,Kazutaka Hosoya et al.
Motohiro Tamiya et al.
Objectives As first line therapy, pembrolizumab provides longer progression free survival (PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) with tumor pro...
Multicenter Study
Investigational new drugs. 2019 Dec;37(6):1266-1273. DOI:10.1007/s10637-019-00843-y 2019
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001) [0.03%]
帕博利珠单抗一线治疗PD-L1阳性≥50%的晚期非小细胞肺癌疗效和安全性回顾性队列研究（HOPE-001）
Motohiro Tamiya,Akihiro Tamiya,Kazutaka Hosoya et al.
Motohiro Tamiya et al.
Objectives As first line therapy, pembrolizumab provides longer progression free survival (PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) with tumor pro...
Multicenter Study
Investigational new drugs. 2019 Dec;37(6):1266-1273. DOI:10.1007/s10637-019-00843-y 2019
Correction to: Inhibitory effects of tea polyphenols by targeting cyclooxygenase-2 through regulation of nuclear factor kappa B, Akt and p53 in rat mammary tumors [0.03%]
题为“茶多酚通过调节核因子κB、Akt和p53靶向环氧合酶-2抑制大鼠乳腺肿瘤的作用”的更正通知
Preeti Roy,Jasmine George,Smita Srivastava et al.
Preeti Roy et al.
The authors regret to inform that there were unknowing errors in figures. The corrected images are given below. These figures are not affecting the results and conclusion of the manuscript. Hence, the text in original paper remains unchange...
Published Erratum
Investigational new drugs. 2019 Dec;37(6):1310-1311. DOI:10.1007/s10637-019-00841-0 2019